Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (20704)	5/13/1998 6:06:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI, I don't have time to dig out the post, but I did say that since LLY didn't own the psoriasis rights (or the other DAB compounds), then LGND should buy the company (SRGN) outright. However, regardless of my prediction, it really isn't at all odd that LGND would talk about buying a specialty cancer company as well as getting rights to a LLy drug and the two events would be related, especially when LGND indicated that the LLY drug would have applications in LGND's areas of interest, i.e. cancer. I had heard that SRGN reps were at conferences that LGND was presenting at and they were talking to LGND (even though SRGN was not presenting). When I saw all of the overlap between ONTAP and Targretin, it didn't take much to figure out that a buyout was clearly being negotiated,